Epinephrine spray formulations
The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
1. An epinephrine spray formulation comprising:
about 2.96% w/w epinephrine base;
about 32.93% w/w hydrochloric acid with a normality of about 0.5N;
about 0.05% w/w edetate disodium dihydrate;
about 0.15% w/w sodium bisulfite;
about 0.01% w/w benzalkonium chloride;
about 0.6% w/w sodium chloride; and
about 63.30% w/w water,
wherein the formulation provides a pharmacokinetic parameter selected from the group consisting of a C max from about 256 to about 418 picograms per milliliter, a T max from about 0.13 to about 0.376 hours, an AUC last of about 231 h*pg/mL, an AUC inf from about 273 to about 377 h*pg/mL and a combination thereof.
2. The formulation of claim 1 , wherein the formulation provides a pharmacokinetic parameter selected from the group consisting of a C max of about 256 picograms per milliliter, a T max of about 0.376 hours, an AUC last of about 231 h*pg/mL, an AUC inf of about 377 h*pg/mL and a combination thereof.
3. The formulation of claim 1 , wherein the human was exposed to an allergen prior to administration.
4. The formulation of claim 3 , wherein the formulation provides a pharmacokinetic parameter selected from the group consisting of a C max of about 418 picograms per milliliter, a T max of about 0.13 hours, an AUC last of about 231 h*pg/mL, an AUC inf of about 273 h*pg/mL and a combination thereof.
5. An epinephrine spray formulation comprising:
about 3.18% w/w epinephrine base;
about 35.47% w/w hydrochloric acid with a normality of about 0.5N;
about 0.05% w/w edetate disodium dihydrate;
about 0.15% w/w sodium bisulfate;
about 0.01% w/w benzalkonium chloride;
about 40.0% w/w ethanol; and
about 16.14% w/w water, and wherein the formulation provides a pharmacokinetic parameter selected from the group consisting of a C max from about 419 to about 639 picograms per milliliter, a T max from about 0.12 to about 0.41 hours, an AUC last from about 429 to about 596 h*pg/mL, an AUC inf from about 497 to about 727 h*pg/mL and a combination thereof.
6. The formulation of claim 5 , wherein the formulation provides a pharmacokinetic parameter selected from the group consisting of a C max of about 419 picograms per milliliter, a T max of about 0.41 hours, an AUC last of about 596 h*pg/mL, an AUC inf of about 727 h*pg/mL and a combination thereof.
7. The formulation of claim 5 , wherein the human was exposed to an allergen prior to administration.
8. The formulation of claim 7 , wherein the formulation provides a pharmacokinetic parameter selected from the group consisting of a C max of about 639 picograms per milliliter, a T max of about 0.12 hours, an AUC last of about 429 h*pg/mL, an AUC inf of about 497 h*pg/mL and a combination thereof.
9. An epinephrine spray formulation comprising:
about 3.675% w/w epinephrine base;
about 21.681% w/w hydrochloric acid with a normality of about 1.0N;
about 0.05% w/w edetate disodium dihydrate;
about 0.184% w/w sodium bisulfate;
about 0.01% w/w benzalkonium chloride;
about 40.0% w/w ethanol;
about 5.0% w/w propylene glycol; and
about 21.681% w/w water,
wherein w/w denotes weight by total weight of the formulation.
10. An epinephrine spray formulation comprising:
about 4.462% w/w epinephrine base;
about 26.241% w/w hydrochloric acid with a normality of about 1.0N;
about 0.05% w/w edetate disodium dihydrate;
about 0.223% w/w sodium bisulfite;
about 0.01% w/w benzalkonium chloride;
about 40.0% w/w ethanol;
about 5.0% w/w propylene glycol; and
about 23.774% w/w water,
wherein w/w denotes weight by total weight of the formulation.